Cite
Dhiman A, Vining CC, Witmer HDD, et al. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022;doi: 10.1245/s10434-021-11249-7.
Dhiman, A., Vining, C. C., Witmer, H. D. D., Sood, D., Shergill, A., Kindler, H., Roggin, K. K., Posner, M. C., Ahmed, O. S., Liauw, S., Pitroda, S., Liao, C. Y., Karrison, T., Weichselbaum, R., Polite, B., Eng, O. S., Catenacci, D. V. T., & Turaga, K. K. (2022). Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Annals of surgical oncology, . https://doi.org/10.1245/s10434-021-11249-7
Dhiman, Ankit, et al. "Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels." Annals of surgical oncology vol. (2022). doi: https://doi.org/10.1245/s10434-021-11249-7
Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KK. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05; doi: 10.1245/s10434-021-11249-7. Epub 2022 Jan 05. PMID: 34988836.
Copy
Download .nbib